Quality of Life Research

, Volume 15, Issue 1, pp 103–115 | Cite as

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension

  • S. P. McKenna
  • N. Doughty
  • D. M. Meads
  • L. C. Doward
  • J. Pepke-Zaba
Article

Abstract

Objective: No outcome measures specific to pulmonary hypertension (PH) currently exist. The aim of the study was to develop health-related quality of life (symptoms and functioning) scales and a quality of life scale that would allow comprehensive, accurate and valid patient-reported outcome assessment in clinical studies. Methods: The content of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was derived from qualitative interviews conducted with 35 patients. Item reduction was based on the analysis of responses to a postal survey (n=75) and patient interviews (n=15) designed to determine face and content validity. A final postal validation study (n=91) was performed to determine reproducibility and construct validity. Results: The questionnaire was well received by participants who found it to be relevant, comprehensible and quick and easy to complete. Rasch and factor analyses were conducted to ensure unidimensionality of the final CAMPHOR scales; Overall symptoms (made up of Energy, Breathlessness and Mood subscales), Functioning and Quality of life. The CAMPHOR scales had good internal consistency (α=0.90–0.92) and reproducibility (test–retest correlations=0.86–0.92). They also exhibited convergent, divergent and known groups validity. Conclusions: The CAMPHOR is a valuable new instrument for assessing patient-reported outcome in PH clinical trials and routine practice.

Keywords

Functioning Health status indicators Pulmonary hypertension Quality of life Symptoms 

Abbreviations

CAMPHOR

Cambridge Pulmonary Hypertension Outcome Review

CTEPH

Chronic Thrombotic and/or Embolic Disease

EQ-5D

EuroQoL

HRQL

health-related quality of life

NHP

Nottingham Health Profile

NSCAG

National Specialist Commissioning Advisory Group

NYHA

New York Heart Association classification

PH

Pulmonary Hypertension

PVDU

Pulmonary Vascular Disease Unit

QoL

Quality of Life

RUMM

Rasch Unidimensional Measurement Model

VAS

visual analogue scale

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubin, LJ 1997Primary pulmonary hypertensionN Engl J Med336111117CrossRefPubMedGoogle Scholar
  2. 2.
    D’Alonzo, GE, Barst, RJ, Ayres, SM,  et al. 1991Survival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Int Med115343349PubMedGoogle Scholar
  3. 3.
    Gibbs, JSR, Higgenbottam, TW 2001Recommendations on the management of pulmonary hypertension in clinical practiceHeart86(Suppl)i1i13Google Scholar
  4. 4.
    Galie, N, Manes, A, Branzi, A 2003Prostanoids for pulmonary arterial hypertensionAm J Respir Med2123137PubMedGoogle Scholar
  5. 5.
    Myers, SA, Ahearn, GS, Angelica Selim, M, Tapson, VF 2004Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapyJ Am Acad Dermatol5198102CrossRefPubMedGoogle Scholar
  6. 6.
    Kadikar, A, Maurer, J, Kesten, S 1997The six-minute walk test: A guide to assessment for lung transplantationJ Heart Lung Transplant16313319PubMedGoogle Scholar
  7. 7.
    Borg, GA 1982Psychophysical bases of perceived exertionMed Sci Sports Exerc14377381PubMedGoogle Scholar
  8. 8.
    Hunt, SM, McEwen, J, McKenna, SP 1986Measuring Health StatusCroom HelmLondonGoogle Scholar
  9. 9.
    EuroQoL Group1990EuroQoL: A new facility for the measurement of health-related quality of lifeHealth Policy16199208Google Scholar
  10. 10.
    Ware, JE, Snow, KK, Kosinski, M, Gandek, B 1993SF-36 Health Survey: Manual and Interpretation GuideThe Health Institute, New England Medical CentreBoston, MAGoogle Scholar
  11. 11.
    Galie, N, Humbert, M, Vachiery, JL,  et al. 2002Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized double-blind, placebo-controlled trialJ Am Coll Cardiol3914961502PubMedGoogle Scholar
  12. 12.
    Simonneau, G, Barst, RJ, Galie, N,  et al. 2002Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med165800804PubMedGoogle Scholar
  13. 13.
    Olschewski, H, Simonneau, G, Galie, N,  et al. 2002Inhaled iloprost for severe pulmonary hypertensionN Engl J Med347322329CrossRefPubMedGoogle Scholar
  14. 14.
    Dixon , P, Heaton, J, Long, A, Warburton, A 1994Reviewing and applying the SF-36Outcomes Briefing August 4325Google Scholar
  15. 15.
    Ziebland, S 1995The short form 36 health status questionnaire: Clues from the Oxford region’s normative data about its usefulness in measuring health gain in population surveysJ Epidemiol Community Health49102105PubMedCrossRefGoogle Scholar
  16. 16.
    Wolfe, F, Hawley, DJ 1997Measurement of the quality of life in rheumatic disorders using the EuroQolBr J Rheumatol36786793CrossRefPubMedGoogle Scholar
  17. 17.
    Rector, RS, Kubo, SH, Cohn, JN 1987Patients’ self-assessment of their congestive heart failureHeart Fail1198209Google Scholar
  18. 18.
    World Health Organization2001International Classification of Functioning, Disability and HealthWHO PublicationGenevaGoogle Scholar
  19. 19.
    Hunt, SM, McKenna, SP 1992The QLDS: A scale for the measurement of quality of life in depressionHealth Policy22307319CrossRefPubMedGoogle Scholar
  20. 20.
    Holmes, SJ, McKenna, SP, Doward, LC, Shalet, SM 1995Development of a questionnaire to assess the quality of life of adults with growth hormone deficiencyEndocrinol Metab26369Google Scholar
  21. 21.
    Wagner, TH, Patrick, DL, McKenna, SP, Froese, MA 1996Cross-cultural development of a quality of life measure for men with erection difficultiesQual Life Res5443449CrossRefPubMedGoogle Scholar
  22. 22.
    Jong, Z, Heijde, D, McKenna, SP, Whalley, D 1997The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrumentBr J Rheumatol36878883PubMedGoogle Scholar
  23. 23.
    McKenna, SP, Doward, LC, Mackenzie Davey, K 1998The development and psychometric properties of the MSQOL; a migraine-specific quality-of-life instrumentClin Drug Invest15413423Google Scholar
  24. 24.
    Doward, LC, McKenna, SP, Kohlmann, T,  et al. 1998The international development of the RGHQoL: A quality of life measure for recurrent genital herpesQual Life Res7143153CrossRefPubMedGoogle Scholar
  25. 25.
    McKenna, SP, Whalley, D, Dewar, AL, Erdman, RA, Kohlman , T, Niero, M,  et al. 2005International development of the Parents’ Index of Quality of life in Atopic Dermatitis (PIQoL-AD)Qual Life Res14231241CrossRefPubMedGoogle Scholar
  26. 26.
    McKenna, SP, Cook, SA, Whalley, D,  et al. 2003Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trialsBr J Dermatol149323331CrossRefPubMedGoogle Scholar
  27. 27.
    Doward, LC, Spoorenberg, A, Cook, SA,  et al. 2003Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitisAnn Rheum Dis622026CrossRefPubMedGoogle Scholar
  28. 28.
    McKenna, SP, Doward, LC, Whalley, D, Tennant, A, Emery, P, Veale, DJ 2004Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritisAnn Rheum Dis63162169CrossRefPubMedGoogle Scholar
  29. 29.
    Rasch, G 1980Probabilistic Models for some Intelligence and Attainment TestsUniversity of Chicago PressChicagoGoogle Scholar
  30. 30.
    Andrich, D 1988Rasch Models for MeasurementSage PublicationsLondonGoogle Scholar
  31. 31.
    Weiner, EA, Stewart, BJ 1984Assessing IndividualsLittle BrownBostonGoogle Scholar
  32. 32.
    Streiner, D, Norman, G 1989Health Measurement ScalesOxford University PressOxfordGoogle Scholar
  33. 33.
    McKenna, SP, Whalley, D, Doward, LC 2000Which outcomes are important in schizophrenia trials?Int J Methods Psychiatr Res9S58S67SupplGoogle Scholar
  34. 34.
    McKenna, SP, Doward, LC 2004The Needs-Based Approach to Quality of Life AssessmentValue Health7S1S3PubMedGoogle Scholar
  35. 35.
    Tennant, A, McKenna, SP, Hagell, P 2004Application of Rasch analysis in the development and application of quality of life instrumentsValue Health7(s1)S22S26Google Scholar
  36. 36.
    Detmar, SB, Muller, MJ, Schornagel, JH,  et al. 2002Health-related quality of life assessments and patient–physician communication: A randomized controlled trialJAMA28830273034CrossRefPubMedGoogle Scholar
  37. 37.
    Doward, LC, McKenna, SP 1997

    Evolution of quality of life assessment

    Rajagopalan, RSheretz, EFAnderson, RT eds. Care Management of Skin Diseases: Life Quality and Economic ImpactMarcel DekkerNew York933
    Google Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • S. P. McKenna
    • 1
  • N. Doughty
    • 2
  • D. M. Meads
    • 1
  • L. C. Doward
    • 1
  • J. Pepke-Zaba
    • 2
  1. 1.Galen Research, Enterprise HouseManchester Science ParkManchesterUK
  2. 2.Pulmonary Vascular Disease Unit, Papworth Hospital NHS TrustCambridgeshireUK

Personalised recommendations